Positron emission tomography (PET) with somatostatin receptor (SSTR) ligands has taken the lead in the imaging of neuroendocrine tumors (NETs). In this article, we review the role of SSTR PET scan in the management of NETs, including the indications for the scan, pitfalls in interpretation, and imaging selection criteria for peptide receptor radionuclide therapy. We also discuss the complementary role of fluorodeoxyglucose PET particularly for patients with high-grade disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.soc.2022.06.009 | DOI Listing |
Publication Analysis
Top Keywords
imaging neuroendocrine
8
neuroendocrine tumors
8
molecular anatomic
4
anatomic imaging
4
tumors positron
4
positron emission
4
emission tomography
4
tomography pet
4
pet somatostatin
4
somatostatin receptor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!